Methadone in Post-Herpetic Neuralgia Pain

Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Post-herpetic Neuralgia Nervous System Diseases Neuralgia Neuralgia, Postherpetic Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with chronic (>6 months) symptomatic PHN
with visual analogical scale >40/100mm
use of first and second line drugs (tricyclic antidepressants, venlafaxine and gabapentinoids)

Exclusion criteria

Don't full the criteria above

Treatment and study plan

Methadone

Drug

patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.

Placebo

Drug

patients with post-herpetic neuralgia take placebo to treat the pain symptoms.

Primary outcomes

Change in baseline Pain

Time frame: baseline (visit inclusion) and three moths latter

Assessing by verbal analog scale (VAS)

Sponsors and collaborators

Lead sponsor

University of Sao Paulo

Other

Registry information

Acronym: NPH

Important dates

Study start: 1998
Primary completion: 2013
Study completion: 2013
First posted: Dec 19, 2012
Registry last updated: Mar 18, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed